Dr. Wise is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
160 East 34th Street
10th Floor
New York, NY 10016Phone+1 212-731-6366Fax+1 212-731-5527
Summary
- My expertise in the management of advanced urologic cancers incorporates the most recently developed imaging and therapeutic modalities and a broad array of targeted and immunotherapy-based clinical trials.
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2013 - 2017
New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 2011 - 2013
OtherClass of 2011
Perelman School of Medicine at the University of PennsylvaniaClass of 2011
Certifications & Licensure
NY State Medical License 2013 - 2025- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Trial of LAVA-1207 in Patients With Therapy Refractory Metastatic Castration Resistant Prostate Cancer (mCRPC) Resistant Prostate Cancer Start of enrollment: 2022 Jun 27
Roles: Contact
Publications & Presentations
PubMed
- Implementation of Universal Germline Genetic Testing Into Standard of Care for Patients With Prostate Cancer: The Time Is Now.Neal Shore, Sarah M Nielsen, Edward D Esplin, Emmanuel S Antonarakis, Pedro C Barata
JCO Oncology Practice. 2024-12-19 - Thrombo-inflammation linking androgen suppression with cardiovascular risk in patients with prostate cancer.Antonia Beitzen-Heineke, David R Wise, Jeffrey S Berger
Cardio-Oncology. 2024-12-05 - Reply by Authors.Neal Shore, Christopher Pieczonka, Sean Heron, Mukaram Gazi, David Cahn
The Journal of Urology. 2024-12-01
Press Mentions
EU Thumbs up for Oral ADT for Prostate CancerFebruary 28th, 2022
Prospective Study Characterizes PCa Risk Linked to BRCA1, BRCA2 MutationsSeptember 24th, 2019
European Urologists Release Position Paper on Immune Checkpoint Inhibitor ToxicitiesAugust 2nd, 2019- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
